7 August 2017

Alligator expands immuno-oncology collaboration with Stanford University


Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX), a biotechnology company developing tumor-directed immunotherapies for cancer treatment, today announced that it has expanded its collaboration with Stanford University to support its biomarker strategy.

The collaboration’s objective is to enable the early prediction of clinical efficacy of Alligator´s pipeline candidates through the analysis of potential systemic biomarkers. In the longer-term, this may benefit patients through appropriate treatment selection based on biomarker analysis. Biomarker selection is critical to the success of this strategy, and Stanford´s expertise, including RNA sequencing and proteomic analysis, will be instrumental in this.

Alligator has worked with Stanford since 2014, drawing on its pioneering work in immuno-oncology. The principal investigator at Stanford, Prof Dean Felsher, is an expert in the field of oncogene-induced cancer immune evasion and the relationship between oncogenes and cancer immunotherapy. The next step in the biomarker program will be to evaluate Alligator´s compounds in Stanford´s pre-clinical models.

“The expanded collaboration with Stanford University will accelerate the pre-clinical development of our pipeline projects and strengthen the biomarker discovery program by drawing on their world-leading expertise in this area. Tumor-directed immunotherapy has the potential to add efficacy without adding dose-limiting toxicity, and the biomarker strategy will be essential to fully deliver on this.”

Per Norlén

CEO of Alligator Bioscience

For further information, please contact:

Per Norlén, CEO
E-mail: per.norlen@alligatorbioscience.com 

Rein Piir, VP Investor Relations
Telephone: +46 708 537292
E-mail: rein.piir@alligatorbioscience.com

Per-Olof Schrewelius, CFO
Telephone: +46 46 286 42 85
E-mail: per-olof.schrewelius@alligatorbioscience.com


The information in the press release was submitted for publication on 7 August 2017 at 08:30 (CET).


About Alligator

Alligator Bioscience is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes lead clinical and pre-clinical product candidates (ADC-1013, ATOR-1015, ATOR-1017, and ALG.APV-527) and novel research candidates. ADC-1013 is licensed to Janssen Biotech, Inc., part of J&J, for development and commercialization. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 45 employees. For more information, please visit www.alligatorbioscience.se.

Back to previous page